



University of Dundee

Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD

Lipworth, Brian J.; Kuo, Chris R. W.

Published in: **European Respiratory Journal**

DOI 10.1183/13993003.02420-2018

Publication date: 2019

Document Version Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA): Lipworth, B. J., & Kuo, C. R. W. (2019). Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD. *European Respiratory Journal*, *53*(2), [1802420]. https://doi.org/10.1183/13993003.02420-2018

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.

- You may not further distribute the material or use it for any profit-making activity or commercial gain.
 You may freely distribute the URL identifying the publication in the public portal.

Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

EUROPEAN RESPIRATORY *journal* of the ers

Cardio-protective effects of inhaled corticosteroid containing combination therapy in COPD

Journal:	European Respiratory Journal
Manuscript ID	Draft
Manuscript Type:	Correspondence
Date Submitted by the Author:	n/a
Complete List of Authors:	Lipworth, Brian; University of Dundee, Scottish Centre for Respiratory Research Kuo, Chris RuiWen; University of Dundee, Scottish Centre For Respiratory Research;
Key Words:	COPD, inhaled corticosteroids, cardiovascular disease
Abstract:	



Cardio-protective effects of inhaled corticosteroid containing combination therapy in COPD

To the editor

The pooled post hoc analysis of three randomised controlled trials by Vestbo et al [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non respiratory related mortality in COPD compared to long acting bronchodilator therapies alone, the difference amounting to -35% (95% CI -57 to -3). These studies did not adjudicate on cause of death and only followed patients for up to one year. In the IMPACT trial all cause mortality was 42 % lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long acting bronchodilators over one year [2].

Another real life analysis used record linkage data from Tayside Scotland among 4133 COPD patients who were studied over a period of 4.6 years [3]. Comparing patients taking any ICS containing combination regimens to those with long acting bronchodilators alone showed an overall significant difference in all cause mortality of -36% (95% CI -20 to -48). Moreover those patients taking triple therapy had a significant difference in both all cause and cardiovascular mortality amounting to a -49% difference (95% CI -59 to -36) and -44% difference (95% CI -65 to -10) respectively. Such patients had a mean FEV1 of 53% predicted, oxygen saturation of 91%, mean age 68 years and 46 pack years of smoking.

This in turn suggests a hypothesis that ICS containing combination therapy may confer cardio-protective effects in patients with COPD. A possible salutary effect of ICS could be suppression of aldosterone which is known to impair cardiac function and promote arrhythmias [4, 5]. It remains unclear whether this putative benefit of ICS might occur in COPD patients with concomitant hypoxaemia which could sensitise ischaemic myocardium [6, 7]. Further prospective trials are now required to test this hypothesis, perhaps in COPD patients stratified by cardiovascular risk using non invasive biomarkers such as high sensitivity troponin and N-terminal pro-hormone B type natriuretic peptide.

Dr Brian Lipworth and Dr Chris Kuo Scottish Centre for Respiratory Research Ninewells Hospital and Medical School Dundee, Scotland, UK DD1 9SY Correspondence: b.j.lipworth@dundee.ac.uk

References

1. Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D. Inhaled corticosteroid containing combinations and mortality in COPD. *Eur Respir J* 2018: 52(6).

 2. Lipson DA, Criner GJ, Lomas DA. Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *N Engl J Med* 2018: 379(6): 592-593.

3. Manoharan A, Short PM, Anderson WJ, Lipworth BJ. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. *Lung* 2014: 192(5): 649-652.

4. Wilson AM, Sims EJ, Struthers AD, Lipworth BJ. Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. *Clinical Science* 1998: 95(4): 513-517.

5. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. *Nat Rev Cardiol* 2013: 10(3): 125-134.

6. Cargill RI, Kiely DG, Lipworth BJ. Adverse effects of hypoxaemia on diastolic filling in humans. *Clin Sci (Lond)* 1995: 89(2): 165-169.

7. Kiely DG, Cargill RI, Grove A, Struthers AD, Lipworth BJ. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. *Thorax* 1995: 50(10): 1062-1066.